The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia

Journal of Neuroendocrinology

Volumn 20, Issue 3, 2008, Pages 366-374

  Farr, Tracy D ^a,c   Carswell, H V O ^a   McCann, D J ^a   Sato, M ^b   Bryant, H U ^b   Dodge, J A ^b   Macrae, I M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ELI LILLY AND COMPANY   (United States)

^c MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

Author keywords

Neuroprotection; Oestrogen; Selective oestrogen receptor modulators; Stroke

Indexed keywords

LY 362321; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRIPHENYLTETRAZOLIUM; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN BLOOD FLOW; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MIDDLE CEREBRAL ARTERY OCCLUSION; MONITORING; NEUROPROTECTION; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SENSORIMOTOR FUNCTION;

ANIMALS; BEHAVIOR, ANIMAL; BONE AND BONES; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR CIRCULATION; CEREBROVASCULAR DISORDERS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ESTRADIOL; ESTRADIOL ANTAGONISTS; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; NEUROPROTECTIVE AGENTS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TUMOR CELLS, CULTURED; UTERUS;

EID: 39549093772     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2008.01648.x     Document Type: Article

References (58)

1. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004; 291: 1701-1712.
2. Gibson CL, Gray LJ, Murphy SP, Bath PM. Estrogens and experimental ischemic stroke: A systematic review. J Cereb Blood Flow Metab 2006; 26: 1103-1113.
3. Hurn PD, Macrae IM. Estrogen as a neuroprotectant in stroke. J Cereb Blood Flow Metab 2000; 20: 631-652.
4. Murphy SJ, McCullough LD, Smith JM. Stroke in the female: Role of biological sex and estrogen. ILAR J 2004; 45: 147-159.
5. Carswell HV, Dominiczak AF, Macrae IM. Estrogen status affects sensitivity to focal cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2000; 278: H290-H294.
6. Alkayed NJ, Murphy SJ, Traystman RJ, Hurn PD, Miller VM. Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke 2000; 31: 161-168.
7. Dubal DB, Kashon ML, Pettigrew LC, Ren JM, Finklestein SP, Rau SW, Wise PM. Estradiol protects against ischemic injury. J Cereb Blood Flow Metab 1998; 18: 1253-1258.
8. Fan T, Yang SH, Johnson E, Osteen B, Hayes R, Day AL, Simpkins JW. 17beta-Estradiol extends ischemic thresholds and exerts neuroprotective effects in cerebral subcortex against transient focal cerebral ischemia in rats. Brain Res 2003; 993: 10-17.
9. Fukuda K, Yao H, Ibayashi S, Nakahara T, Uchimura H, Fujishima M, Hall ED. Ovariectomy exacerbates and estrogen replacement attenuates photothrombotic focal ischemic brain injury in rats. Stroke 2000; 31: 155-160.
10. He Z, He YJ, Day AL, Simpkins JW. Proestrus levels of estradiol during transient global cerebral ischemia improves the histological outcome of the hippocampal CA1 region: Perfusion-dependent and-independent mechanisms. J Neurol Sci 2002; 193: 79-87.
11. Rusa R, Alkayed NJ, Crain BJ, Traystman RJ, Kimes AS, London ED, Klaus JA, Hurn PD. 17beta-estradiol reduces stroke injury in estrogen-deficient female animals. Stroke 1999; 30: 1665-1670.
12. Simpkins JW, Rajakumar G, Zhang YQ, Simpkins CE, Greenwald D, Yu CJ, Bodor N, Day AL. Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J Neurosurg 1997; 87: 724-730.
13. Wang Q, Santizo R, Baughman VL, Pelligrino DA, Iadecola C. Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats. Stroke 1999; 30: 630-637.
14. Zhang YQ, Shi J, Rajakumar G, Day AL, Simpkins JW. Effects of gender and estradiol treatment on focal brain ischemia. Brain Res 1998; 784: 321-324.
15. Wise PM, Dubal DB. Estradiol protects against ischemic brain injury in middle-aged rats. Biol Reprod 2000; 63: 982-985.
16. Toung TJ, Traystman RJ, Hurn PD. Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke 1998; 29: 1666-1670.
17. Hawk T, Zhang YQ, Rajakumar G, Day AL, Simpkins JW. Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res 1998; 796: 296-298.
18. Yang SH, Shi J, Day AL, Simpkins JW. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 2000; 31: 745-749.
19. Vergouwen MD, Anderson RE, Meyer FB. Gender differences and the effects of synthetic exogenous and non-synthetic estrogens in focal cerebral ischemia. Brain Res 2000; 878: 88-97.
20. Bingham D, Macrae IM, Carswell HV. Detrimental effects of 17beta-oestradiol after permanent middle cerebral artery occlusion. J Cereb Blood Flow Metab 2005; 25: 414-420.
21. Gordon KB, Macrae IM, Carswell HV. Effects of 17beta-oestradiol on cerebral ischaemic damage and lipid peroxidation. Brain Res 2005; 1036: 155-162.
22. Harukuni I, Hurn PD, Crain BJ. Deleterious effect of beta-estradiol in a rat model of transient forebrain ischemia. Brain Res 2001; 900: 137-142.
23. Theodorsson A, Theodorsson E. Estradiol increases brain lesions in the cortex and lateral striatum after transient occlusion of the middle cerebral artery in rats: No effect of ischemia on galanin in the stroke area but decreased levels in the hippocampus. Peptides 2005; 26: 2257-2264.
24. Carswell HV, Bingham D, Wallace K, Nilsen M, Graham DI, Dominiczak AF, Macrae IM. Differential effects of 17beta-estradiol upon stroke damage in stroke prone and normotensive rats. J Cereb Blood Flow Metab 2004; 24: 298-304.
25. Littleton-Kearney MT, Ostrowski NL, Cox DA, Rossberg MI, Hurn PD. Selective estrogen receptor modulators: Tissue actions and potential for CNS protection. CNS Drug Rev 2002; 8: 309-330.
26. Murphy S, McCullough L, Littleton-Kearney M, Hurn P. Estrogen and selective estrogen receptor modulators: Neuroprotection in the Women's Health Initiative era. Endocrine 2003; 21: 17-26.
27. Katzenellenbogen BS, Katzenellenbogen JA. Biomedicine. Defining the 'S' in SERMs. Science 2002; 295: 2380-2381.
28. Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat Res 2005; 591: 247-263.
29. Rossberg MI, Murphy SJ, Traystman RJ, Hurn PD. LY353381.HCl, a selective estrogen receptor modulator, and experimental stroke. Stroke 2000; 31: 3041-3046.
30. Kimelberg HK, Feustel PJ, Jin Y, Paquette J, Boulos A, Keller RW Jr, Tranmer BI. Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. Neuroreport 2000; 11: 2675-2679.
31. Kimelberg HK, Jin Y, Charniga C, Feustel PJ. Neuroprotective activity of tamoxifen in permanent focal ischemia. J Neurosurg 2003; 99: 138-142.
32. Mehta SH, Dhandapani KM, De Sevilla LM, Webb RC, Mahesh VB, Brann DW. Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat. Neuroendocrinology 2003; 77: 44-50.
33. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999; 281: 2189-2197.
34. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 1995; 99: 636-641.
35. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5years of treatment. J Natl Cancer Inst 1994; 86: 1534-1539.
36. Bertelli G, Venturini M, Del Mastro L, Garrone O, Cosso M, Gustavino C, Cusimano E, Guido T, Nicolo G, Rosso R. Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res Treat 1998; 47: 41-46.
37. Geiser AG, Hummel CW, Draper MW, Henck JW, Cohen IR, Rudmann DG, Donnelly KB, Adrian MD, Shepherd TA, Wallace OB, McCann DJ, Oldham SW, Bryant HU, Sato M, Dodge JA. A new selective estrogen receptor modulator with potent uterine antagonist activity, agonist activity in bone, and minimal ovarian stimulation. Endocrinology 2005; 146: 4524-4535.
38. Wallace OB, Lauwers KS, Dodge JA, May SA, Calvin JR, Hinklin R, Bryant HU, Shetler PK, Adrian MD, Geiser AG, Sato M, Burris TP. A selective estrogen receptor modulator for the treatment of hot flushes. J Med Chem 2006; 49: 843-846.
39. Simpkins J, Katovich MJ, Song IC. Similarities between morphine withdrawl in the rat and menopausal hot flush. Life Sci 1983; 32: 1957-1966.
40. Merchanthaler I, Funkhouser JM, Carver JM, Lundeen SG, Ghosh K, Winneker RC. The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas 1998; 30: 307-316.
41. Komm BS, Lyttle CR. Developing a SERM: Stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann NY Acad Sci 2001; 949: 317-326.
42. Sayeed I, Wali B, Stein DG. Progesterone inhibits ischemic brain inury in a rat model of permanent middle cerebral artery occlusion. Restor Neurol Neurosci. 2007; 25: 151-159.
43. Koizumi J, Yoshida Y, Nakazawa T, Ohneda G. Experimental studies of ischemic brain edema, I: A new experimental model of cerebral embolism in rats in which recirculation can be introduced in the ischemic area. Jpn J Stroke 1986; 8: 1-8.
44. Soriano MA, Sanz O, Ferrer I, Planas AM. Cortical infarct volume is dependent on the ischemic reduction of perifocal cerebral blood flow in a three-vessel intraluminal MCA occlusion/reperfusion model in the rat. Brain Res 1997; 747: 273-278.
45. Hunter AJ, Hatcher J, Virley D, Nelson P, Irving E, Hadingham SJ, Parsons AA. Functional assessments in mice and rats after focal stroke. Neuropharmacology 2000; 39: 806-816.
46. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000; 39: 777-787.
47. Richardson TI, Frank SA, Wang M, Clarke CA, Jones SA, Ying BP, Kohlman DT, Wallace OB, Shepherd TA, Dally RD, Palkowitz AD, Geiser AG, Bryant HU, Henck JW, Cohen IR, Rudmann DG, McCann DJ, Coutant DE, Oldham SW, Hummel CW, Fong KC, Hinklin R, Lewis G, Tian H, Dodge JA. Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety. Bioorg Med Chem Lett 2007; 17: 3544-3549.
48. Dirnagl U. Bench to bedside: The quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006; 26: 1465-1478.
49. Phillis JW, Song D, O'Regan MH. Tamoxifen, a chloride channel blocker, reduces glutamate and aspartate release from the ischemic cerebral cortex. Brain Res 1998; 780: 352-355.
50. Zhang Y, Jin Y, Behr MJ, Feustel PJ, Morrison JP, Kimelberg HK. Behavioral and histological neuroprotection by tamoxifen after reversible focal cerebral ischemia. Exp Neurol 2005; 196: 41-46.
51. Shughrue PJ, Merchenthaler I. Estrogen prevents the loss of CA1 hippocampal neurons in gerbils after ischemic injury. Neuroscience 2003; 116: 851-861.
52. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-645.
53. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001; 65: 125-134.
54. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-1761.
55. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: Preliminary enrollment data from a randomized breast cancer risk reduction trial. Clin Breast Cancer 2002; 3: 153-159.
56. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL III, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741.
57. Mosca L. Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann NY Acad Sci. 2001; 949: 181-185.
58. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-137.